Panorama™

Panorama™

Panorama™

cost of natera panorama test without insurance

References

1Natera internal data on file

2Definitive Healthcare report to identify billing for NIPT based on US Clearinghouse for Medical Claims using CPT codes 81420, 81507, 81422.

3Dar et al. Am J Obstet Gynecol. 2022 Aug;227(2):259.e1-259.e14.

4ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.

5Dar et al. Am J Obstet Gynecol. 2022. https://doi.org/10.1016/j.ajog.2022.01.002

6Kantor V, et al. Prenat Diagn. 2022 Jul;42(8):994-999.

7DiNonno et al. J Clin Med. 2019 Aug 26;8(9):1311.

8Martin et al. ISUOG World Congress 2022: September, 2022.

9Nicolaides KH et al. Fetal Diagn Ther. 2014;35(3):212-7. https://doi.org/10.1159/000355655

10Kantor V, et al. Prenat Diagn. 2022 Dec;42(13).

11Martin K et al. Genet in Med. 2023. doi: https://doi.org/10.1016/j.gim.2023.100879

12Martin et al. Clin Genet. 2018 Feb;93(2):293-300.

13Wapner et al. Am J Obstet Gynecol. 2015 Mar;212(3):332.e1-9.

14Norwitz et al. J Clin Med. 2019 Jun; 8:937.

Footnotes

* CA residents: If your clinician ordered screening through the California Prenatal Screening program using Natera’s Vasistera™ NIPT, Panorama™ will only screen for supplemental conditions. If this is the case, trisomies 21, 18 and 13, and fetal sex (optional) will be screened using Vasistera™ NIPT and will be reported separately.

** Not available for egg-donor or gestational carrier pregnancies or in cases of dizygotic (nonidentical) twins. Triploidy and microdeletions except for 22q11.2 deletions are not available for monozygotic (identical) twins.

† This test has been validated on full region deletions of Prader-Willi syndrome/Angelman syndrome (PWS/AS) only and might be unable to detect smaller deletions. It has not been validated for other molecular mechanisms which could cause PWS/AS such as uniparental disomy (UPD) or methylation.

‡ Ongoing clinical follow-up is performed to ensure the NPV does not fall below the quoted value but follow up is not obtained for all low risk calls.

§ PPV for 22q11.2 deletion syndrome and Angelman syndrome in published studies was 53% and 10% respectively when no ultrasound anomalies were seen and was up to 100% when ultrasound anomalies were seen prior to testing.

|| Dependent upon fetal fraction (FF). For 22q11.2 deletion syndrome, only the paternal allele is evaluated at FF ≤ 6.5%. For 1p36 deletion syndrome and Cri-du-chat syndrome, only the paternal allele is evaluated at FF < 7%. For Angelman syndrome, no risk assessment is reported at FF < 7%. For Prader-Willi syndrome, no risk assessment is reported at FF ≤ 2.8%.

This post was last modified on December 9, 2024 3:43 pm